Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study

INTRODUCTION: To evaluate long-term efficacy of once-daily baricitinib 2 mg in patients with active rheumatoid arthritis who had an inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) or biologic DMARDs (bDMARD). METHODS: Data from patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wells, Alvin F., Jia, Bochao, Xie, Li, Valenzuela, Guillermo J., Keystone, Edward C., Li, Zhanguo, Quebe, Amanda K., Griffing, Kirstin, Otawa, Susan, Haraoui, Boulos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217400/
https://www.ncbi.nlm.nih.gov/pubmed/34028703
http://dx.doi.org/10.1007/s40744-021-00317-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217400/
https://www.ncbi.nlm.nih.gov/pubmed/34028703
http://dx.doi.org/10.1007/s40744-021-00317-9

Ejemplares similares